Biosig Technologies (NASDAQ:STEX) Chairman Morgan Lee Lekstrom Purchases 50,000 Shares

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom acquired 50,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was purchased at an average cost of $0.99 per share, with a total value of $49,500.00. Following the transaction, the chairman owned 359,500 shares in the company, valued at approximately $355,905. This trade represents a 16.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 28th, Morgan Lee Lekstrom acquired 34,000 shares of Biosig Technologies stock. The stock was purchased at an average cost of $1.47 per share, with a total value of $49,980.00.
• On Thursday, May 21st, Morgan Lee Lekstrom bought 147,000 shares of Biosig Technologies stock. The shares were acquired at an average price of $1.04 per share, with a total value of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total transaction of $13,652.13.

Biosig Technologies Trading Up 6.5%

Shares of NASDAQ:STEX traded up $0.06 on Monday, hitting $1.04. The company had a trading volume of 1,331,623 shares, compared to its average volume of 1,856,985. Biosig Technologies, Inc. has a 1-year low of $0.70 and a 1-year high of $14.11. The company has a market cap of $188.17 million, a PE ratio of -0.11 and a beta of 1.85. The stock’s 50 day moving average is $1.07.

Biosig Technologies (NASDAQ:STEX) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) EPS for the quarter.

Analyst Ratings Changes

STEX has been the subject of a number of recent research reports. Wall Street Zen cut shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research report on Sunday, April 5th. Needham & Company LLC reduced their target price on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. Finally, Weiss Ratings raised shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biosig Technologies presently has an average rating of “Hold” and a consensus price target of $8.00.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.